Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | active not recruiting | Phase 4 | 134 | Novartis PharmaceuticalsINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT00904410 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET(CHIMTEP) | completed | Phase 4 | 63 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05206331 | CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study | completed | Phase 4 | 2,089 | Margarita Louise ZuleyOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients(STRIDE) | active not recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04016376 | Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction | completed | Phase 4 | 1,507 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT05562518 | GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.(GRACE) | completed | Phase 4 | 31 | University Hospital, GhentOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06162663 | Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors | terminated | Phase 4 | 6 | Medical University of South CarolinaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | recruiting | Phase 4 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07490509 | Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer(DOSABEMA) | not yet recruiting | Phase 4 | 235 | Poitiers University HospitalOTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07252726 | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers | recruiting | Phase 4 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05754528 | Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance(REaCT-TEMPO) | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07600164 | Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer | recruiting | Phase 4 | 500 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07220967 | A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement | recruiting | Phase 4 | 392 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05631795 | Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment(ALPINIST) | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05365230 | A Randomized Trial Evaluating Personalized vs Guideline-based Well Follow-up Strategies for Patients With Early-stage Breast Cancer | completed | Phase 4 | 261 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03664687 | Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)(REaCT-ZOL) | completed | Phase 4 | 211 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06169371 | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)(BRE-09) | recruiting | Phase 4 | 50 | University of Illinois at ChicagoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05183126 | Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | recruiting | Phase 4 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | recruiting | Phase 4 | 10 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04928261 | Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | active not recruiting | Phase 4 | 52 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07630948 | Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer(riboADHERE) | not yet recruiting | Phase 4 | 90 | Institute of Oncology LjubljanaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | terminated | Phase 4 | 62 | University of WashingtonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04921137 | Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | recruiting | Phase 4 | 500 | Ottawa Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04764292 | Screening Contrast-Enhanced Mammography as an Alternative to MRI(SCEMAM) | completed | Phase 4 | 615 | Wendie BergOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07583134 | Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery(B-BIT) | not yet recruiting | Phase 4 | 100 | Chang-Ik YoonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT01553903 | Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not(OXYTAM) | completed | Phase 4 | 29 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01612871 | Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer(MIRHO) | completed | Phase 4 | 39 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07487129 | Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt(Clinical and P) | completed | Phase 4 | 206 | Beni-Suef UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04024254 | A Study of Serum Folate Levels in Patients Treated With Olaparib | completed | Phase 4 | 10 | Rush University Medical CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07436663 | Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC(SGLT2i/DPPi) | not yet recruiting | Phase 4 | 150 | Tanta UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07042581 | A Study of Revaree Plus in People With Breast Cancer | recruiting | Phase 4 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | not yet recruiting | Phase 4 | 78 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT04864405 | Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance | completed | Phase 4 | 245 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07308717 | Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | recruiting | Phase 4 | 1,896 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT02696707 | An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer(OTT 15-05) | completed | Phase 4 | 200 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05222464 | Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study | completed | Phase 4 | 56 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07254221 | Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients(ROSUBREAST) | not yet recruiting | Phase 4 | 400 | Shiraz University of Medical SciencesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02688803 | Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)(OTT15-04) | terminated | Phase 4 | 2 | Ottawa Hospital Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06072807 | Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer | recruiting | Phase 4 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06574022 | Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks | recruiting | Phase 4 | 100 | University of CincinnatiOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05807074 | Impact of Topical Tranexamic Acid in Breast Reconstruction | terminated | Phase 4 | 23 | University of California, San FranciscoOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT06491680 | Cardiotoxicity in Breast Cancer Patients | recruiting | Phase 4 | 40 | Helwan UniversityOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05871437 | Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules | not yet recruiting | Phase 4 | 232 | Fudan UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials